• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

New Self-Test Kit Can Detect Cancer and Prevent Heart Failure – with a Simple Prick of the Finger

by HITC Staff 08/25/2015 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
New Self-Test Kit Can Detect Cancer and Prevent Heart Failure – with a Simple Prick of the Finger
Before and after: The Dr Now test kits (right) make it easier than ever to have a reliable blood test, eradicating the need for painful injections and unnecessary trips to the clinic.

 

Dr Now, a UK-based medical diagnostic and delivery mobile platform from Now Healthcare Group, has unveiled a self-test ‘tumor marker’ kits to help diagnose ovarian cancer and assess the severity of potential future heart failure. The self diagnosis test kits allow patients to administer a thorough blood test themselves, simply by pricking their finger and providing a small blood sample. Results are then returned to the patient within 24 hours of the sample being received by the Dr Now lab.

How It Works

Tumour markers are substances that are produced by cells in response to cancer or certain benign conditions. They are produced at higher levels in cancerous conditions than normal, which makes them detectable through a simple blood test. The NT-Pro (BNP) test helps to diagnose and assess the severity of a potential heart failure, and can be effective up to 15 years before the heart fails. This preventative test can allow those at risk to receive the necessary treatment to minimize the risk of a future heart problem. The CA125 blood test is used to diagnose ovarian cancer. It detects above-normal levels of the tumour marker CA125, while the related HE4 test considers the risk factor of malignancy.

These new tests offered by Dr Now complements the company’s current diagnosis and medication delivery service offered to patients directly from an app-based video consultation with an MRCGP-certified GP. Currently in a ‘soft launch’ phase, the Dr Now platform will be fully launched in October 2015. The Dr Now app is now available to download for iOS and Android devices from the App Store and Google Play.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |